EST
KRYS icon

EA Series Trust’s Krystal Biotech KRYS Stock Holding History

EA Series Trust’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$2.83M Buy
+24,101
New +$2.46M 0.1% 293

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EA Series Trust's KRYS Position: Q2 2023 in Review

EA Series Trust opened a new position in Krystal Biotech (KRYS) in Q2 2023: 24,101 shares worth $2.83M. The stake represents 0.1% of the portfolio and ranks #293 among its holdings.

183 funds tracked by Wall St. Rank hold KRYS as of Q2 2023.

  • EA Series Trust held 24,101 shares of Krystal Biotech worth $2.83M as of Q2 2023.
  • Krystal Biotech was a new EA Series Trust position in Q2 2023.
  • Krystal Biotech made up 0.1% of EA Series Trust's portfolio in Q2 2023, its #293 holding.
  • 183 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.